HMT is anecdotally reported for the treatment of resistant APL cases and the rationale for their use has been postulated by the study of Soncini et al. where they show TRAIL-dependent apoptosis of APL and AML blasts [57]. The gene discussed is TNFSF10; the disease is acute promyelocytic leukemia.